TS-23 is under clinical development by Translational Sciences and currently in Phase I for Ischemic Stroke. According to GlobalData, Phase I drugs for Ischemic Stroke have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TS-23’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TS-23 overview

DS-9231 (TS23) is under development for thrombosis, acute pulmonary embolism, myocardial infarction and ischemic stroke. It is a blood clot dissolving agent. The drug candidate is an alpha 2 plasmin inhibitor. It is administered through intravenous route.

For a complete picture of TS-23’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.